# A Distillation of Melanoma Statistics 

From the Canadian Cancer Society Documents Canadian Cancer Statistics 2017: Special Topic: Pancreatic Cancers (2017) with comparisons to Canadian Cancer Statistics 2016: Special Topic: HPVAssociated Cancers Save Your Skin Foundation - June 2017

## Melanoma Statistics 2017

* There are estimated to be 103,100 new cases of cancer in MALES in 2017. Of these, $3.9 \%$ are estimated to be melanoma (201721. Figure 1.2). In 2016, there were estimated to be 102,900 new cases of cancer in MALES, $3.6 \%$ of these being melanoma (2016 19. Figure 1.2).
* There are estimated to be 103,200 new cases of cancer in FEMALES in 2017. Of these, 3.2\% are expected to be melanoma (2017 21. Figure 1.2). In 2016, there were estimated to be 99,500 new cases of cancer in FEMALES, $3.1 \%$ of these being melanoma (2016 19. Figure 1.2).
* Incidence rates of melanoma have increased in both males and females over the last decade. Between 1992-2013 incidence rates increased by 2.1\% per year in MALES and 2\% per year in FEMALES (201726).
* 2017 page 37. Table 1.1: MALES
* 2017 lifetime probability of developing melanoma: 1.8\% (2016 page 26.

Table 1.1: 2016 lifetime probability of developing melanoma 1.7\%)

* One in: 56 (2016 page 26. Table 1.1: one in 57)
* Probability (\%) of developing melanoma in the next 10 years at selected ages:
$30-0.1 \%, 40-0.1 \%, 50-0.2 \%, 60-0.4 \%, 70-0.6 \%, 80-0.7 \%$ (2016 page 26. Table 1.1:
$30-0.1 \%, 40-0.1 \%, 50-0.2 \%, 60-0.4 \%, 70-0.6 \%, 80-0.6 \%)$
* 2017 page 37. Table 1.1: FEMALES
* Lifetime probability of developing melanoma: 1.4\% (2016 page 26. Table
1.1: 2016 lifetime probability of developing melanoma 1.3\%)
* One in: 74 (2016 page 26. Table 1.1: one in 74)
* Probability (\%) of developing cancer in the next 10 years at selected ages:
$30-0.1 \%, 40-0.2 \%, 50-0.2 \%, 60-0.3 \%, 70-0.3 \%, 80-0.3 \%$ (2016 page 26. Table 1.1:
$30-0.1 \%, 40-0.2 \%, 50-0.2 \%, 60-0.3 \%, 70-0.3 \%, 80-0.3 \%)$
* 2017 page 38. Table 1.2: New cases of melanoma
* TOTAL: 7,200 (18.5 per 100,000) (2016 27. Table 1.2: 6,800 (17.8 per 100,000))
* MALE: 4,000 (21.3 per 100,000) (2016 27. Table 1.2: 3,700 (20.5 per 100,000))
* FEMALE: 3,300 (16.3 per 100,000) (2016 27. Table 1.2: 3,100 (15.8 per 100,000))
* 2017 page 39. Table 1.3: age-standardized incidence rates (ASIR) for selected cancers, MALES, Canada, 1988-2017

TABLE 1.3 Age-standardized incidence rates (ASIR) for selected* cancers, males, Canada, 1988-2017*

| Year | Cases per 100,000 |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{array}{r} \text { All } \\ \text { cancers } \end{array}$ | Prostate | Colorectal | Lung and bronchus | Bladder | Melanoma | Stomach | Liver | Thyroid | Larynx |
| 1988 | 608.9 | 122.3 | 84.9 | 126.3 | 44.2 | 12.6 | 23.1 | 3.9 | 2.5 | 11.6 |
| 1989 | 598.5 | 123.3 | 83.2 | 123.6 | 40.7 | 11.5 | 22.5 | 4.1 | 2.4 | 10.9 |
| 1990 | 605.4 | 133.6 | 83.0 | 122.5 | 40.2 | 12.6 | 21.2 | 4.4 | 2.5 | 10.2 |
| 1991 | 622.6 | 150.0 | 83.0 | 120.1 | 40.8 | 11.3 | 21.0 | 4.6 | 2.8 | 11.1 |
| 1992 | 648.4 | 167.5 | 85.5 | 121.5 | 40.8 | 13.0 | 19.7 | 4.6 | 2.3 | 10.9 |
| 1993 | 662.2 | 186.4 | 82.1 | 122.5 | 40.6 | 13.0 | 19.4 | 5.0 | 3.0 | 10.0 |
| 1994 | 646.6 | 171.9 | 83.3 | 115.9 | 40.7 | 13.5 | 19.3 | 5.7 | 3.1 | 10.1 |
| 1995 | 615.2 | 149.4 | 81.3 | 113.3 | 39.9 | 13.8 | 18.0 | 5.5 | 3.0 | 9.8 |
| 1996 | 603.7 | 146.7 | 79.8 | 110.4 | 38.3 | 14.0 | 18.4 | 5.6 | 3.0 | 9.3 |
| 1997 | 608.2 | 154.1 | 79.7 | 106.9 | 39.7 | 14.4 | 17.6 | 6.1 | 3.1 | 8.8 |
| 1998 | 608.9 | 154.0 | 82.5 | 108.2 | 38.0 | 14.1 | 17.2 | 5.7 | 3.2 | 8.8 |
| 1999 | 623.6 | 159.5 | 83.8 | 107.3 | 40.5 | 16.4 | 17.0 | 6.1 | 3.7 | 8.8 |
| 2000 | 626.5 | 166.3 | 85.9 | 102.4 | 38.8 | 16.0 | 16.7 | 6.1 | 4.1 | 7.8 |
| 2001 | 634.8 | 177.4 | 84.7 | 102.5 | 37.6 | 16.4 | 16.1 | 7.0 | 4.0 | 8.2 |
| 2002 | 614.2 | 165.4 | 83.8 | 99.3 | 37.7 | 15.5 | 14.8 | 7.0 | 4.6 | 7.7 |
| 2003 | 608.9 | 161.1 | 81.0 | 96.4 | 38.4 | 16.4 | 15.9 | 6.7 | 4.3 | 7.1 |
| 2004 | 615.4 | 164.2 | 82.6 | 96.5 | 38.6 | 16.3 | 15.3 | 7.2 | 4.6 | 7.1 |
| 2005 | 614.4 | 163.5 | 82.5 | 95.0 | 37.4 | 16.2 | 15.1 | 7.8 | 5.5 | 7.0 |
| 2006 | 615.3 | 169.1 | 81.4 | 93.0 | 37.4 | 17.5 | 14.6 | 7.9 | 5.8 | 6.3 |
| 2007 | 618.3 | 168.0 | 81.7 | 92.6 | 36.7 | 17.8 | 14.4 | 8.5 | 6.0 | 6.4 |
| 2008 | 604.4 | 154.6 | 82.3 | 89.9 | 38.2 | 18.7 | 14.0 | 8.3 | 6.6 | 6.5 |
| 2009 | 597.2 | 151.3 | 80.2 | 88.4 | 37.6 | 19.2 | 13.6 | 8.7 | 6.6 | 6.2 |
| 2010 | 584.3 | 146.1 | 76.3 | 86.1 | 37.7 | 19.2 | 12.8 | 8.5 | 6.8 | 6.3 |
| $2011{ }^{\text {+ }}$ | 587.3 | 147.7 | 77.3 | 83.2 | 38.0 | 19.5 | 12.9 | 9.2 | 8.0 | 5.9 |
| 2012 ${ }^{\text { }}$ | 562.0 | 128.8 | 75.4 | 82.1 | 36.5 | 19.0 | 12.4 | 9.3 | 8.5 | 5.5 |
| 2013 | 553.8 | 117.2 | 75.3 | 78.9 | 35.7 | 20.0 | 12.6 | 8.7 | 8.6 | 5.3 |
| 2014: | 559.1 | 117.7 | 80.1 | 79.8 | 36.6 | 21.1 | 12.2 | 9.4 | 8.3 | 5.4 |
| $2015{ }^{\text { }}$ | 555.4 | 115.1 | 79.9 | 78.7 | 36.5 | 21.2 | 12.1 | 9.6 | 8.5 | 5.3 |
| $2016^{\text { }}$ | 551.9 | 112.7 | 79.7 | 77.5 | 36.4 | 21.3 | 11.9 | 9.8 | 8.6 | 5.2 |
| 2017 ${ }^{\text { }}$ | 548.4 | 110.4 | 79.6 | 76.5 | 36.3 | 21.3 | 11.8 | 9.9 | 8.8 | 5.1 |

* 2017 page 40. Table 1.4: age-standardized incidence rates (ASIR) for selected cancers, FEMALES, Canada, 1988-2017

TABLE 1.4 Age-standardized incidence rates (ASIR) for selected* cancers, females, Canada, 1988-2017 ${ }^{\dagger}$

| Year | Cases per 100,000 |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{array}{r} \text { All } \\ \text { cancers } \end{array}$ | Breast | Lung and bronchus | Colorectal | Uterus (body,NOS) | Thyroid | Melanoma | Bladder | Cervix | Liver | Larynx |
| 1988 | 435.9 | 126.2 | 45.7 | 60.8 | 26.6 | 5.7 | 10.6 | 12.0 | 11.2 | 1.4 | 2.0 |
| 1989 | 427.2 | 124.2 | 46.1 | 59.8 | 24.7 | 6.1 | 10.0 | 10.4 | 11.1 | 1.5 | 2.1 |
| 1990 | 431.2 | 124.0 | 47.9 | 60.0 | 25.1 | 6.3 | 9.9 | 10.5 | 11.5 | 1.3 | 1.9 |
| 1991 | 437.4 | 130.0 | 49.4 | 58.3 | 24.9 | 6.5 | 10.2 | 10.6 | 10.6 | 1.4 | 2.2 |
| 1992 | 446.6 | 132.7 | 52.8 | 58.7 | 25.0 | 7.4 | 10.0 | 10.1 | 10.8 | 1.8 | 1.8 |
| 1993 | 447.4 | 129.5 | 54.0 | 58.7 | 26.2 | 7.7 | 10.6 | 10.9 | 10.6 | 1.6 | 1.7 |
| 1994 | 446.8 | 129.2 | 52.8 | 57.6 | 25.8 | 8.2 | 10.7 | 10.5 | 10.3 | 1.8 | 1.9 |
| 1995 | 444.3 | 129.0 | 54.1 | 56.1 | 24.8 | 8.3 | 11.0 | 10.6 | 10.2 | 1.7 | 1.9 |
| 1996 | 442.3 | 129.1 | 55.8 | 54.7 | 24.8 | 8.4 | 11.3 | 9.9 | 10.2 | 1.8 | 1.8 |
| 1997 | 448.4 | 134.1 | 56.0 | 55.0 | 25.5 | 8.5 | 11.2 | 10.2 | 9.4 | 1.7 | 1.8 |
| 1998 | 458.7 | 135.6 | 57.9 | 58.1 | 26.0 | 8.8 | 11.3 | 11.0 | 9.3 | 2.1 | 1.6 |
| 1999 | 459.5 | 138.0 | 57.9 | 56.9 | 25.7 | 10.3 | 11.9 | 10.3 | 9.3 | 1.6 | 1.6 |
| 2000 | 461.2 | 133.7 | 59.8 | 58.3 | 26.1 | 11.1 | 12.2 | 9.8 | 9.1 | 2.0 | 1.4 |
| 2001 | 457.9 | 131.5 | 59.6 | 57.3 | 25.5 | 12.0 | 12.3 | 10.0 | 9.0 | 2.0 | 1.5 |
| 2002 | 464.0 | 134.0 | 60.4 | 56.7 | 26.4 | 14.2 | 11.9 | 9.9 | 8.7 | 1.9 | 1.4 |
| 2003 | 455.2 | 126.5 | 60.4 | 55.7 | 26.3 | 14.7 | 11.9 | 10.5 | 8.5 | 2.1 | 1.5 |
| 2004 | 458.3 | 127.0 | 61.3 | 56.3 | 25.9 | 16.1 | 12.4 | 10.3 | 8.3 | 1.9 | 1.3 |
| 2005 | 465.7 | 127.8 | 63.1 | 56.0 | 26.1 | 18.2 | 12.9 | 10.4 | 7.9 | 2.1 | 1.2 |
| 2006 | 465.7 | 127.8 | 63.5 | 54.4 | 26.9 | 18.4 | 13.1 | 10.2 | 8.1 | 2.4 | 1.1 |
| 2007 | 471.4 | 128.4 | 63.7 | 55.0 | 27.9 | 19.6 | 13.7 | 10.5 | 8.4 | 2.3 | 1.3 |
| 2008 | 468.9 | 126.0 | 64.6 | 54.9 | 27.7 | 21.1 | 14.2 | 9.8 | 8.1 | 2.5 | 1.1 |
| 2009 | 474.6 | 128.7 | 64.1 | 54.4 | 28.3 | 21.7 | 14.8 | 10.5 | 8.4 | 2.2 | 1.1 |
| 2010 | 475.8 | 130.2 | 63.1 | 53.9 | 30.2 | 22.7 | 14.4 | 9.8 | 8.2 | 2.4 | 1.0 |
| $2011{ }^{\text {+ }}$ | 479.4 | 130.8 | 63.3 | 53.1 | 30.6 | 25.8 | 15.0 | 10.2 | 7.9 | 2.5 | 1.1 |
| $2012^{\prime}$ | 477.3 | 127.2 | 64.4 | 53.0 | 31.3 | 27.1 | 14.6 | 10.2 | 7.6 | 2.7 | 0.9 |
| 2013 | 477.5 | 126.9 | 63.6 | 51.7 | 30.6 | 27.1 | 15.9 | 9.5 | 7.5 | 2.3 | 0.8 |
| 2014 | 492.5 | 129.7 | 66.0 | 55.1 | 34.7 | 27.4 | 16.1 | 9.9 | 8.4 | 2.6 | 0.9 |
| $2015{ }^{\text { }}$ | 493.6 | 129.9 | 65.8 | 55.0 | 35.0 | 28.0 | 16.2 | 9.9 | 8.4 | 2.6 | 0.9 |
| 2016 ${ }^{\text { }}$ | 494.6 | 130.0 | 65.6 | 54.9 | 35.4 | 28.5 | 16.3 | 9.8 | 8.3 | 2.6 | 0.9 |
| $2017{ }^{\text { }}$ | 495.6 | 130.3 | 65.3 | 54.9 | 35.7 | 29.1 | 16.3 | 9.8 | 8.3 | 2.7 | 0.8 |

* 2017 page 41: annual percent change (ACP) in age-standardized incidence rates for selected cancers, by sex, Canada, most recent trends to 2013
* melanoma MALE annual percent change 2.1\% (reference year 1992)
* melanoma FEMALE annual percent change 2\% (reference year 1992)
* 2017 page 44. Table 1.9: Projected new cases for selected cancers, by sex and province, Canada, 2017

TABLE 1.9 Projected new cases for selected cancers, by sex and province, Canada, 2017

|  | Canada* | BC | AB | SK | MB | ON ${ }^{+}$ | QC ${ }^{\text { }}$ | NB | NS | PE | NL |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Males |  |  |  |  |  |  |  |  |  |  |  |
| All cancers | 103,100 | 12,900 | 9,700 | 2,800 | 3,300 | 39,800 | 26,300 | 2,400 | 3,100 | 470 | 2,000 |
| Prostate | 21,300 | 2,800 | 2,400 | 590 | 700 | 8,500 | 4,800 | 370 | 620 | 95 | 450 |
| Colorectal | 14,900 | 1,850 | 1,250 | 500 | 510 | 5,700 | 3,800 | 380 | 470 | 70 | 360 |
| Lung and bronchus | 14,400 | 1,500 | 1,100 | 370 | 430 | 5,300 | 4,400 | 420 | 470 | 75 | 320 |
| Bladder | 6,700 | 970 | 650 | 220 | 230 | 1,850 | 2,200 | 210 | 240 | 30 | 140 |
| Non-Hodgkin lymphoma | 4,600 | 580 | 460 | 100 | 150 | 1,850 | 1,050 | 110 | 150 | 20 | 90 |
| Kidney and renal pelvis | 4,200 | 490 | 410 | 130 | 140 | 1,550 | 1,100 | 110 | 150 | 20 | 85 |
| Melanoma | 4,000 | 590 | 360 | 80 | 110 | 1,900 | 560 | 90 | 160 | 25 | 55 |
| Leukemia | 3,600 | 460 | 420 | 130 | 110 | 1,500 | 770 | 110 | 90 | 10 | 40 |
| Oral | 3,200 | 420 | 310 | 80 | 130 | 1,350 | 700 | 70 | 100 | 20 | 50 |
| Pancreas | 2,800 | 380 | 240 | 80 | 80 | 1,050 | 700 | 75 | 75 | 15 | 40 |
| Stomach | 2,200 | 250 | 180 | 70 | 85 | 850 | 570 | 60 | 60 | 10 | 65 |
| Liver | 1,900 | 300 | 180 | 30 | 45 | 760 | 480 | 20 | 40 | 5 | 20 |
| Esophagus | 1,800 | 240 | 190 | 45 | 50 | 760 | 380 | 40 | 65 | 10 | 25 |
| Brain/CNS | 1,700 | 210 | 160 | 50 | 50 | 650 | 460 | 35 | 45 | 10 | 30 |
| Multiple myeloma | 1,700 | 210 | 170 | 45 | 55 | 700 | 400 | 40 | 45 | 10 | 25 |
| Thyroid | 1,650 | 140 | 160 | 25 | 35 | 710 | 450 | 35 | 35 | 5 | 30 |
| Testis | 1,100 | 160 | 140 | 35 | 40 | 420 | 250 | 20 | 25 | 5 | 10 |
| Larynx | 970 | 120 | 85 | 25 | 35 | 330 | 290 | 30 | 35 | 5 | 20 |
| Hodgkin lymphoma | 570 | 60 | 60 | 20 | 20 | 210 | 160 | 10 | 15 | - | 10 |
| Breast | 230 | 30 | 15 | 5 | 5 | 95 | 60 | 5 | 10 | - | 5 |
| Females |  |  |  |  |  |  |  |  |  |  |  |
| All cancers | 103,200 | 12,600 | 8,800 | 2,800 | 3,400 | 40,900 | 26,900 | 2,300 | 3,100 | 440 | 1,850 |
| Breast | 26,300 | 3,500 | 2,600 | 750 | 860 | 10,100 | 6,500 | 580 | 730 | 120 | 510 |
| Lung and bronchus | 14,200 | 1,550 | 1,100 | 420 | 480 | 5,300 | 4,300 | 290 | 480 | 60 | 220 |
| Colorectal | 11,900 | 1,500 | 970 | 380 | 360 | 4,700 | 3,000 | 270 | 400 | 60 | 270 |
| Uterus (body, NOS) | 7,300 | 970 | 650 | 180 | 280 | 3,200 | 1,450 | 150 | 180 | 20 | 150 |
| Thyroid | 5,400 | 360 | 390 | 90 | 110 | 2,500 | 1,650 | 100 | 120 | 10 | 100 |
| Non-Hodgkin lymphoma | 3,700 | 520 | 290 | 110 | 130 | 1,550 | 830 | 95 | 110 | 15 | 80 |
| Melanoma | 3,300 | 510 | 310 | 75 | 100 | 1,500 | 470 | 90 | 130 | 25 | 45 |
| Ovary | 2,800 | 350 | 210 | 75 | 90 | 1,200 | 710 | 55 | 75 | 10 | 40 |
| Pancreas | 2,700 | 330 | 260 | 75 | 95 | 1,100 | 690 | 70 | 75 | 10 | 35 |
| Leukemia | 2,600 | 330 | 240 | 80 | 85 | 1,100 | 550 | 75 | 60 | 10 | 20 |
| Kidney and renal pelvis | 2,400 | 210 | 200 | 80 | 95 | 900 | 610 | 80 | 110 | 10 | 60 |
| Bladder | 2,200 | 290 | 200 | 70 | 75 | 560 | 790 | 60 | 90 | 10 | 35 |
| Cervix | 1,550 | 180 | 170 | 50 | 50 | 710 | 280 | 25 | 45 | 5 | 30 |
| Oral | 1,450 | 180 | 120 | 35 | 60 | 600 | 370 | 30 | 40 | 5 | 15 |
| Brain/CNS | 1,300 | 150 | 110 | 35 | 40 | 510 | 380 | 30 | 30 | 5 | 20 |
| Stomach | 1,300 | 140 | 95 | 30 | 40 | 540 | 330 | 30 | 30 | 5 | 35 |
| Multiple myeloma | 1,200 | 150 | 110 | 35 | 40 | 510 | 270 | 30 | 35 | 5 | 20 |
| Liver | 580 | 85 | 50 | 10 | 15 | 210 | 180 | 10 | 10 | - | 10 |
| Esophagus | 530 | 80 | 45 | 10 | 15 | 220 | 120 | 10 | 20 | 5 | 5 |
| Hodgkin lymphoma | 430 | 50 | 40 | 15 | 15 | 180 | 100 | 10 | 10 | - | 5 |
| Larynx | 180 | 20 | 15 | 5 | 5 | 55 | 55 | 5 | 10 | - | 5 |

* 2016 page 39. Table 2.4: estimated new cases for selected cancers by sex and province, Canada, 2016

TABLE 2.4 Estimated new cases for selected cancers by sex and province, Canada, 2016

|  | Canada* | BC | AB | SK | MB | ON' | QC ${ }^{4}$ | NB | NS | PE | NL* |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Males |  |  |  |  |  |  |  |  |  |  |  |
| All cancers | 102,900 | 13,200 | 9,900 | 3,000 | 3,400 | 39,400 | 25,800 | 2,600 | 3,000 | 470 | 2,100 |
| Prostate | 21,600 | 3,300 | 2,600 | 660 | 710 | 7,900 | 4,700 | 530 | 590 | 95 | 440 |
| Colorectal | 14,500 | 1,800 | 1,300 | 480 | 560 | 5,400 | 3,700 | 360 | 470 | 70 | 360 |
| Lung and bronchus | 14,400 | 1,550 | 1,050 | 330 | 430 | 5,300 | 4,400 | 410 | 470 | 65 | 330 |
| Bladider | 6,600 | 1,050 | 660 | 250 | 220 | 1,750 | 2,100 | 190 | 240 | 35 | 110 |
| Non-Hodgkin lymphoma | 4,400 | 560 | 460 | 120 | 150 | 1,700 | 1,050 | 120 | 140 | 20 | 80 |
| Kidney and renal pelvis | 4,100 | 430 | 380 | 130 | 180 | 1,450 | 1,050 | 130 | 150 | 20 | 110 |
| Melanoma | 3,700 | 580 | 360 | 75 | 100 | 1,750 | 550 | 95 | 150 | 20 | 55 |
| Leukemia | 3,500 | 460 | 430 | 130 | 150 | 1,350 | 750 | 100 | 90 | 10 | 45 |
| Oral | 3,200 | 430 | 290 | 95 | 150 | 1,250 | 680 | 65 | 95 | 20 | 55 |
| Pancreas | 2,600 | 350 | 230 | 80 | 95 | 960 | 680 | 65 | 70 | 10 | 35 |
| Stomach | 2,200 | 260 | 190 | 70 | 85 | 790 | 560 | 60 | 60 | 10 | 65 |
| Liver | 1,800 | 290 | 170 | 30 | 45 | 740 | 450 | 20 | 45 | 5 | 20 |
| Esophagus | 1,800 | 240 | 200 | 45 | 50 | 760 | 370 | 40 | 60 | 10 | 20 |
| Bran'CNS | 1,750 | 200 | 160 | 45 | 50 | 680 | 460 | 35 | 45 | 5 | 30 |
| Multiple myeloma | 1,600 | 200 | 150 | 40 | 50 | 630 | 390 | 40 | 45 | 10 | 25 |
| Thyroid | 1,550 | 130 | 150 | 25 | 35 | 670 | 420 | 35 | 35 | - | 25 |
| Testis | 1,100 | 150 | 120 | 35 | 40 | 440 | 240 | 20 | 25 | 5 | 5 |
| Larynx | 890 | 95 | 70 | 25 | 30 | 330 | 290 | 25 | 35 | 5 | 25 |
| Hodgkin lymphoma | 550 | 60 | 65 | 25 | 15 | 210 | 160 | 10 | 15 | - | 10 |
| Females |  |  |  |  |  |  |  |  |  |  |  |
| All cancers | 99,500 | 12,400 | 8,600 | 2,800 | 3,400 | 38,300 | 26,100 | 2,300 | 3,000 | 440 | 1,900 |
| Breast. | 25,700 | 3,500 | 2,400 | 720 | 880 | 9,900 | 6,300 | 570 | 790 | 120 | 440 |
| Lung and bronchus | 14,000 | 1,550 | 1,100 | 420 | 490 | 5,200 | 4,200 | 320 | 480 | 55 | 230 |
| Colorectal | 11,600 | 1,400 | 900 | 360 | 410 | 4,500 | 3,000 | 260 | 420 | 55 | 260 |
| Body of uterus and utenus NOS | 6,600 | 790 | 610 | 180 | 260 | 2,800 | 1,450 | 140 | 160 | 20 | 120 |
| Thyroid | 5,300 | 380 | 370 | 70 | 140 | 2,500 | 1,550 | 110 | 110 | 10 | 110 |
| Non-Hodgkin lymphoma | 3,600 | 480 | 340 | 120 | 130 | 1,450 | 820 | 95 | 120 | 15 | 80 |
| Melanoma | 3,100 | 530 | 290 | 65 | 110 | 1,350 | 460 | 90 | 140 | 20 | 45 |
| Ovary | 2,800 | 320 | 210 | 80 | 100 | 1,150 | 700 | 55 | 70 | 10 | 45 |
| Pancreas | 2,600 | 290 | 240 | 75 | 85 | 1,000 | 680 | 60 | 80 | 10 | 35 |
| Leukemia | 2,400 | 320 | 240 | 85 | 80 | 1,000 | 540 | 70 | 55 | 10 | 25 |
| Kidney and renal pelvis | 2,300 | 200 | 220 | 80 | 95 | 870 | 600 | 80 | 100 | 5 | 60 |
| Bladder | 2,100 | 290 | 190 | 75 | 70 | 520 | 780 | 65 | 80 | 10 | 30 |
| Cervor | 1,500 | 180 | 170 | 50 | 50 | 630 | 280 | 30 | 45 | 5 | 30 |
| Oral | 1,450 | 180 | 110 | 35 | 55 | 600 | 360 | 30 | 40 | 5 | 20 |
| Stomach | 1,300 | 150 | 95 | 35 | 40 | 530 | 320 | 30 | 30 | - | 35 |
| Brain/CNS | 1,300 | 150 | 110 | 35 | 40 | 520 | 370 | 30 | 35 | - | 20 |
| Mutiple myeloma | 1,150 | 160 | 110 | 35 | 35 | 470 | 270 | 25 | 35 | 5 | 20 |
| Liver | 590 | 80 | 55 | 10 | 15 | 210 | 180 | 10 | 10 | - | 5 |
| Esophagus | 530 | 80 | 45 | 10 | 15 | 210 | 110 | 10 | 20 | - | 10 |
| Hodgkin lymphoma | 460 | 55 | 45 | 15 | 15 | 170 | 100 | 5 | 10 | - | 5 |
| Larynx | 170 | 25 | 15 | 5 | 5 | 60 | 60 | 5 | 5 | - | 5 |

* 2017 page 47. Figure 2.2: there are expected to be 42,600 MALE cancer deaths in 2017. Of these, $1.9 \%$ are expected to be caused by melanoma (2016 42. Figure 3.2: estimated male cancer deaths: 41,700 , percentage due to melanoma $1.8 \%$ )
* 2017 page 47. Figure 2.2: there are expected to be 38,200 FEMALE cancer deaths in 2017, 1.2\% being caused by melanoma (2016 42. Figure 3.2: estimated female cancer deaths: 37,100 , percentage due to melanoma $1.2 \%$ )
* 2017 page 53. Figure 2.6: average annual percent change in age-standardized melanoma mortality rates 1992-2012: MALE 1\%, FEMALE 0.3\%
* 2017 page 61. Table 2.1: Lifetime probability of dying from cancer overall and at selected ages, Canada, 2012

TABLE 2.1 Lifetime probability of dying from cancer overall and at selected ages, Canada, 2012

|  | Lifetime probability of dying from cancer overall |  | Probability (\%) of dying from cancer in the next 10 years at selected ages |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | \% | One in: | 30 | 40 | 50 | 60 | 70 | 80 |
| Males |  |  |  |  |  |  |  |  |
| All cancers | 28.3 | 3.5 | 0.1 | 0.5 | 1.8 | 5.0 | 10.4 | 15.9 |
| Lung and bronchus | 7.4 | 14 | - | 0.1 | 0.5 | 1.6 | 3.2 | 3.8 |
| Prostate | 3.5 | 29 | - | - | 0.1 | 0.3 | 0.9 | 2.6 |
| Colorectal | 3.5 | 29 | - | 0.1 | 0.2 | 0.6 | 1.3 | 2.0 |
| Pancreas | 1.4 | 72 | - | - | 0.1 | 0.3 | 0.5 | 0.7 |
| Bladder | 1.2 | 83 | - | - | - | 0.1 | 0.4 | 0.9 |
| Leukemia | 1.1 | 90 | - | - | 0.1 | 0.2 | 0.4 | 0.7 |
| Non-Hodgkin lymphoma | 1.1 | 95 | - | - | 0.1 | 0.2 | 0.4 | 0.6 |
| Esophagus | 0.9 | 112 | - | - | 0.1 | 0.2 | 0.3 | 0.4 |
| Stomach | 0.8 | 126 | - | - | 0.1 | 0.1 | 0.3 | 0.4 |
| Kidney and renal pelvis | 0.7 | 142 | - | - | 0.1 | 0.2 | 0.2 | 0.4 |
| Brain/CNS | 0.6 | 163 | - | - | 0.1 | 0.2 | 0.2 | 0.2 |
| Multiple myeloma | 0.6 | 179 | - | - | - | 0.1 | 0.2 | 0.3 |
| Liver* | 0.5 | 199 | - | - | 0.1 | 0.1 | 0.2 | 0.2 |
| Oral | 0.5 | 206 | - | - | 0.1 | 0.1 | 0.2 | 0.2 |
| Melanoma | 0.4 | 241 | - | - | - | 0.1 | 0.1 | 0.2 |
| Larynx | 0.2 | 459 | - | - | - | 0.1 | 0.1 | 0.1 |
| Thyroid | 0.1 | 1,512 | - | - | - | - | - | - |
| Females |  |  |  |  |  |  |  |  |
| All cancers | 23.7 | 4.2 | 0.2 | 0.6 | 1.8 | 3.9 | 7.3 | 10.4 |
| Lung and bronchus | 5.7 | 17 | - | 0.1 | 0.5 | 1.2 | 2.2 | 2.2 |
| Breast | 3.2 | 31 | 0.1 | 0.2 | 0.3 | 0.5 | 0.8 | 1.2 |
| Colorectal | 2.9 | 34 | - | 0.1 | 0.2 | 0.4 | 0.7 | 1.5 |
| Pancreas | 1.5 | 66 | - | - | 0.1 | 0.3 | 0.5 | 0.7 |
| Ovary | 1.0 | 100 | - | - | 0.1 | 0.2 | 0.3 | 0.4 |
| Non-Hodgkin lymphoma | 0.9 | 116 | - | - | - | 0.1 | 0.3 | 0.5 |
| Leukemia | 0.8 | 122 | - | - | - | 0.1 | 0.3 | 0.4 |
| Uterus (body, NOS) | 0.6 | 154 | - | - | 0.1 | 0.1 | 0.2 | 0.2 |
| Stomach | 0.5 | 199 | - | - | - | 0.1 | 0.1 | 0.3 |
| Brain/CNS | 0.5 | 203 | - | - | 0.1 | 0.1 | 0.1 | 0.2 |
| Bladder | 0.5 | 219 | - | - | - | - | 0.1 | 0.3 |
| Kidney and renal pelvis | 0.5 | 221 | - | - | - | 0.1 | 0.1 | 0.2 |
| Multiple myeloma | 0.4 | 234 | - | - | - | 0.1 | 0.1 | 0.2 |
| Esophagus | 0.3 | 333 | - | - | - | 0.1 | 0.1 | 0.1 |
| Melanoma | 0.3 | 397 | - | - | - | - | 0.1 | 0.1 |
| Cervix | 0.2 | 426 | - | - | - | - | 0.1 | 0.1 |
| Oral | 0.2 | 443 | - | - | - | - | 0.1 | 0.1 |
| Liver* | 0.1 | 672 | - | - | - | - | 0.1 | 0.1 |
| Larynx | 0.1 | 1,662 | - | - | - | - | - | - |
| Thyroid | 0.1 | 1,703 | - | - | - | - | - | - |

* 2017 page 62: Table 2.2: Projected deaths and age-standardized mortality rates (ASMR) for selected cancers, by sex, Canada, 2017

TABLE 2.2 Projected deaths and age-standardized mortality rates (ASMR) for selected cancers, by sex, Canada, 2017

|  | Deaths |  |  | Deaths per 100,000 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Total* | Males | Females | Total* | Males | Females |
| All cancers | 80,800 | 42,600 | 38,200 | 198.1 | 233.3 | 172.1 |
| Lung and bronchus | 21,100 | 11,100 | 10,000 | 51.4 | 59.4 | 45.3 |
| Colorectal | 9,400 | 5,100 | 4,300 | 23.1 | 28.1 | 19.0 |
| Breast | 5,000 | 60 | 5,000 | 12.6 | 0.3 | 23.2 |
| Pancreas | 4,800 | 2,400 | 2,400 | 11.9 | 13.1 | 10.8 |
| Prostate | 4,100 | 4,100 | - | - | 23.8 | - |
| Leukemia | 2,900 | 1,650 | 1,250 | 7.2 | 9.2 | 5.5 |
| Non-Hodgkin lymphoma | 2,700 | 1,500 | 1,200 | 6.7 | 8.4 | 5.3 |
| Bladder | 2,400 | 1,700 | 680 | 5.7 | 9.5 | 2.9 |
| Brain/CNS | 2,400 | 1,350 | 1,050 | 6.0 | 7.1 | 5.0 |
| Esophagus | 2,200 | 1,650 | 480 | 5.3 | 8.9 | 2.1 |
| Stomach | 2,100 | 1,250 | 790 | 5.1 | 6.9 | 3.6 |
| Kidney and renal pelvis | 1,900 | 1,200 | 670 | 4.6 | 6.6 | 3.0 |
| Ovary | 1,800 | - | 1,800 | - | - | 8.2 |
| Multiple myeloma | 1,450 | 810 | 650 | 3.5 | 4.4 | 2.9 |
| Oral | 1,250 | 860 | 400 | 3.1 | 4.6 | 1.8 |
| Melanoma | 1,250 | 790 | 450 | 3.1 | 4.3 | 2.1 |
| Liver ${ }^{1}$ | 1,200 | 950 | 270 | 3.0 | 5.0 | 1.2 |
| Uterus (body, NOS) | 1,150 | - | 1,150 | - | - | 5.3 |
| Larynx | 440 | 350 | 95 | 1.1 | 1.9 | 0.4 |
| Cervix | 400 | - | 400 | - | - | 2.0 |
| Thyroid | 220 | 95 | 120 | 0.5 | 0.5 | 0.5 |
| Hodgkin lymphoma | 140 | 85 | 60 | 0.4 | 0.5 | 0.3 |
| Testis | 45 | 45 | - | - | 0.2 | - |
| All other cancers | 10,400 | 5,500 | 4,900 | 25.5 | 30.7 | 21.6 |

* 2017 page 65. Table 2.5: annual percent change (APC) in age-standardized mortality rates for selected cancers, by sex, Canada, most recent trends to 2012
* MALE annual percent change for melanoma was 1\% (reference year 1992)
* FEMALE annual percent change for melanoma was $0.3 \%$ (reference year 1992)
* 2017 page 68. Table 2.9: Projected deaths for selected cancers, by sex and province, Canada, 2017

TABLE 2.9 Projected deaths for selected cancers, by sex and province, Canada, 2017

|  | Canada* | BC | AB | SK | MB | ON | QC | NB | NS | PE | NL |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Males |  |  |  |  |  |  |  |  |  |  |  |
| All cancers | 42,600 | 5,500 | 3,600 | 1,250 | 1,500 | 15,600 | 11,400 | 1,150 | 1,450 | 210 | 850 |
| Lung and bronchus | 11,100 | 1,300 | 830 | 300 | 340 | 3,700 | 3,600 | 350 | 380 | 60 | 230 |
| Colorectal | 5,100 | 690 | 460 | 150 | 190 | 1,750 | 1,350 | 120 | 200 | 25 | 140 |
| Prostate | 4,100 | 570 | 420 | 160 | 170 | 1,600 | 880 | 95 | 120 | 20 | 75 |
| Pancreas | 2,400 | 350 | 190 | 75 | 75 | 940 | 590 | 60 | 75 | 10 | 40 |
| Bladder | 1,700 | 250 | 140 | 55 | 55 | 630 | 420 | 40 | 55 | 10 | 25 |
| Esophagus | 1,650 | 250 | 180 | 55 | 70 | 670 | 300 | 45 | 65 | 10 | 25 |
| Leukemia | 1,650 | 210 | 140 | 55 | 60 | 670 | 400 | 40 | 55 | 10 | 25 |
| Non-Hodgkin lymphoma | 1,500 | 190 | 120 | 50 | 55 | 550 | 410 | 45 | 60 | 5 | 25 |
| Brain/CNS | 1,350 | 160 | 120 | 30 | 35 | 560 | 330 | 30 | 45 | 5 | 20 |
| Stomach | 1,250 | 130 | 110 | 35 | 50 | 470 | 340 | 35 | 40 | 5 | 45 |
| Kidney and renal pelvis | 1,200 | 180 | 110 | 45 | 55 | 410 | 290 | 35 | 50 | 5 | 25 |
| Liver ${ }^{\text {r }}$ | 950 | 160 | 85 | 15 | 25 | 400 | 220 | 10 | 25 | - | 10 |
| Oral | 860 | 130 | 75 | 20 | 25 | 350 | 190 | 20 | 25 | 5 | 15 |
| Multiple myeloma | 810 | 100 | 70 | 25 | 35 | 310 | 200 | 20 | 30 | 5 | 10 |
| Melanoma | 790 | 95 | 65 | 20 | 25 | 320 | 200 | 20 | 30 | - | 10 |
| Larynx | 350 | 40 | 30 | 10 | 10 | 120 | 110 | 10 | 15 | - | 10 |
| Thyroid | 95 | 15 | 5 | 5 | 5 | 35 | 20 | 5 | 5 | - | - |
| Hodgkin lymphoma | 85 | 10 | 5 | 5 | - | 35 | 25 | - | 5 | - | - |
| Breast | 60 | 5 | 5 | 5 | - | 20 | 15 | - | 5 | - | - |
| Testis | 45 | 5 | 5 | - | - | 15 | 10 | - | - | - | - |
| Females |  |  |  |  |  |  |  |  |  |  |  |
| All cancers | 38,200 | 4,800 | 3,100 | 1,150 | 1,400 | 14,000 | 10,400 | 950 | 1,300 | 200 | 670 |
| Lung and bronchus | 10,000 | 1,200 | 810 | 300 | 350 | 3,400 | 3,100 | 250 | 350 | 55 | 140 |
| Breast | 5,000 | 610 | 410 | 160 | 190 | 1,900 | 1,300 | 120 | 160 | 25 | 100 |
| Colorectal | 4,300 | 630 | 330 | 130 | 160 | 1,500 | 1,200 | 95 | 170 | 30 | 95 |
| Pancreas | 2,400 | 300 | 220 | 70 | 80 | 940 | 630 | 65 | 75 | 10 | 35 |
| Ovary | 1,800 | 250 | 160 | 55 | 65 | 690 | 430 | 45 | 60 | 10 | 30 |
| Leukemia | 1,250 | 160 | 110 | 40 | 40 | 500 | 300 | 30 | 40 | 10 | 20 |
| Non-Hodgkin lymphoma | 1,200 | 160 | 95 | 40 | 50 | 460 | 270 | 35 | 50 | 5 | 20 |
| Uterus (body, NOS) | 1,150 | 140 | 90 | 25 | 35 | 470 | 320 | 25 | 40 | 5 | 20 |
| Brain/CNS | 1,050 | 140 | 70 | 25 | 25 | 450 | 250 | 20 | 30 | 5 | 15 |
| Stomach | 790 | 95 | 60 | 20 | 25 | 310 | 220 | 20 | 25 | - | 25 |
| Bladder | 680 | 100 | 45 | 20 | 25 | 260 | 180 | 15 | 20 | 5 | 10 |
| Kidney and renal pelvis | 670 | 75 | 60 | 15 | 25 | 250 | 170 | 20 | 25 | 5 | 20 |
| Multiple myeloma | 650 | 85 | 60 | 20 | 25 | 240 | 170 | 20 | 20 | 5 | 15 |
| Esophagus | 480 | 75 | 45 | 15 | 15 | 200 | 95 | 10 | 20 | - | 10 |
| Melanoma | 450 | 50 | 35 | 10 | 10 | 190 | 110 | 10 | 15 | 5 | 5 |
| Cervix | 400 | 50 | 45 | 20 | 20 | 150 | 80 | 10 | 15 | 5 | 10 |
| Oral | 400 | 55 | 35 | 10 | 15 | 140 | 110 | 10 | 15 | - | 5 |
| Liver ${ }^{\text {t }}$ | 270 | 35 | 20 | 5 | 10 | 120 | 65 | 5 | 5 | - | 5 |
| Thyroid | 120 | 20 | 10 | - | 5 | 50 | 25 | 5 | 5 | - | 5 |
| Layynx | 95 | 10 | 5 | - | - | 30 | 40 | - | 5 | - | - |
| Hodgkin lymphoma | 60 | 5 | 5 | - | - | 25 | 20 | - | - | - | - |

* 2016 page 61. Table 4.4: estimated deaths for selected cancers by sex and province, Canada, 2016

TABLE 4.4 Estimated deaths for selected cancers by sex and province, Canada, 2016

|  | Canada* | BC | AB | SK | MB | ON | QC | NB | NS | PE | NL |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Males |  |  |  |  |  |  |  |  |  |  |  |
| All cancers | 41,700 | 5,400 | 3,600 | 1,250 | 1,450 | 15,400 | 11,100 | 1,100 | 1,400 | 190 | 780 |
| Lung and bronchus | 10,900 | 1,250 | 810 | 290 | 330 | 3,700 | 3,500 | 340 | 370 | 60 | 220 |
| Colarectal | 5,000 | 670 | 450 | 150 | 190 | 1,700 | 1,350 | 120 | 200 | 25 | 130 |
| Prostare | 4,000 | 560 | 410 | 160 | 170 | 1,550 | 860 | 95 | 120 | 20 | 75 |
| Pancreas | 2,400 | 340 | 190 | 70 | 75 | 910 | 580 | 60 | 75 | 10 | 40 |
| Bladder | 1,650 | 250 | 140 | 55 | 55 | 610 | 410 | 40 | 55 | 10 | 25 |
| Leukemia | 1,650 | 210 | 140 | 55 | 60 | 650 | 400 | 40 | 55 | 5 | 25 |
| Esophagus | 1,600 | 250 | 170 | 55 | 70 | 650 | 290 | 40 | 60 | 10 | 25 |
| Non-Hodgkin lymphoma | 1,500 | 190 | 120 | 45 | 55 | 550 | 400 | 45 | 55 | 5 | 25 |
| Brain/CNS | 1,300 | 160 | 120 | 30 | 35 | 540 | 320 | 30 | 45 | 5 | 20 |
| Stomach | 1,250 | 130 | 110 | 35 | 50 | 460 | 330 | 35 | 40 | 5 | 40 |
| Kidney and renal pelvs | 1,200 | 170 | 100 | 40 | 55 | 410 | 290 | 35 | 45 | 5 | 25 |
| Liver | 910 | 160 | 85 | 15 | 20 | 380 | 210 | 10 | 20 | - | 10 |
| Oral | 840 | 130 | 75 | 20 | 25 | 330 | 190 | 20 | 25 | 5 | 15 |
| Multiple myeloma | 800 | 100 | 70 | 25 | 30 | 310 | 200 | 15 | 30 | 5 | 10 |
| Melanoma | 770 | 90 | 65 | 20 | 25 | 320 | 190 | 20 | 30 | - | 10 |
| Laryix | 320 | 40 | 25 | 10 | 10 | 120 | 110 | 10 | 10 | - | 10 |
| Thyroid | 90 | 15 | 5 | 5 | 5 | 35 | 20 | 5 | 5 | - | - |
| Hodgkin lymphoma | 80 | 10 | 5 | 5 | - | 30 | 25 | - | 5 | - | - |
| Testis | 40 | 5 | 5 | - | - | 15 | 10 | - | - | - | - |
| Females |  |  |  |  |  |  |  |  |  |  |  |
| All cancers | 37,100 | 4,700 | 3,000 | 1,100 | 1,350 | 13,600 | 10,200 | 920 | 1,300 | 190 | 670 |
| Lung and bronchus | 9,800 | 1,200 | 790 | 290 | 350 | 3,400 | 3,000 | 250 | 350 | 50 | 140 |
| Breast | 4,900 | 610 | 410 | 160 | 190 | 1,850 | 1,300 | 120 | 160 | 25 | 100 |
| Colorectal | 4,300 | 610 | 320 | 130 | 160 | 1,500 | 1,200 | 95 | 170 | 25 | 90 |
| Pancreas | 2,400 | 290 | 210 | 65 | 80 | 910 | 620 | 70 | 75 | 10 | 30 |
| Orary | 1,750 | 250 | 150 | 55 | 65 | 680 | 420 | 45 | 55 | 10 | 30 |
| Non-Hodgkin lymphoma | 1,200 | 160 | 90 | 35 | 50 | 460 | 270 | 35 | 50 | 5 | 20 |
| Leukemia | 1,200 | 160 | 110 | 40 | 40 | 490 | 290 | 30 | 40 | 10 | 15 |
| Body of uterus and uterus NOS | 1,100 | 130 | 85 | 25 | 35 | 450 | 300 | 25 | 40 | 5 | 20 |
| Brain/CNS | 1,000 | 130 | 75 | 25 | 25 | 440 | 240 | 20 | 30 | - | 15 |
| Stomach | 780 | 90 | 60 | 20 | 25 | 300 | 210 | 20 | 20 | - | 20 |
| Bladder | 670 | 95 | 45 | 20 | 25 | 260 | 180 | 15 | 20 | 5 | 10 |
| Kidney and renal pelvis | 660 | 70 | 55 | 15 | 25 | 250 | 170 | 20 | 25 | 5 | 20 |
| Multiple myeloma | 640 | 80 | 55 | 20 | 25 | 240 | 170 | 20 | 15 | 5 | 15 |
| Esophagus | 460 | 75 | 40 | 15 | 15 | 190 | 85 | 10 | 20 | - | 10 |
| Melanoma | 440 | 50 | 35 | 10 | 10 | 190 | 110 | 10 | 15 | 5 | 5 |
| Cervix | 400 | 50 | 40 | 20 | 20 | 150 | 80 | 10 | 15 | 5 | 10 |
| Oral | 390 | 55 | 35 | 10 | 15 | 150 | 110 | 10 | 15 | - | 5 |
| Liver ${ }^{\text {a }}$ | 270 | 35 | 20 | 5 | 10 | 120 | 60 | 5 | 5 | - | 5 |
| Thyraid | 120 | 20 | 10 | - | 5 | 45 | 25 | 5 | 5 | - | 5 |
| Laryox | 75 | 10 | 5 | - | - | 30 | 40 | - | 5 | - | - |
| Hodgkin lymphama | 45 | 5 | 5 | - | - | 25 | 15 | - | - | - | - |

* 2017 page 72: five-year survival for melanoma was the second highest in both MALES (85\%) and FEMALES (92\%)
* 2017 page 77. Table 3.1: Five-year age-standardized net and observed survival for selected cancers by sex, ages 15-99, Canada (excluding Quebec), 2006-2008

TABLE 3.1 Five-year age-standardized net and observed survival for selected cancers by sex, ages 15-99, Canada (excluding Quebec*), 2006-2008

|  | Net survival (\%) (95\% confidence interval) |  |  | Observed survival proportion (\%) ( $95 \%$ confidence interval) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Both sexes | Males | Females | Both sexes | Males | Females |
| All cancers | 60 (60-61) | 60 (59-60) | 61 (60-61) | 55 (55-56) | 54 (54-54) | 56 (56-57) |
| Thyroid | 98 (97-98) | 95 (94-97) | 98 (98-99) | 95 (94-95) | 92 (91-93) | 96 (95-96) |
| Testis | - | 96 (95-97) | - | - | 95 (94-96) | - |
| Prostate | - | 95 (94-95) | - | - | 81 (81-82) | - |
| Melanoma | 88 (87-89) | 85 (83-86) | 92 (90-93) | 79 (78-80) | 75 (74-76) | $84(83-85)$ |
| Breast | 87 (87-88) | 79 (72-84) | 87 (87-88) | 80 (80-81) | 71 (65-75) | 80 (80-81) |
| Hodgkin lymphoma | 85 (83-86) | 83 (80-85) | 87 (85-89) | 83 (81-84) | 80 (78-82) | 86 (83-87) |
| Uterus (body, NOS) | - | - | 84 (83-85) | - | - | 78 (77-79) |
| Bladdert | 73 (72-74) | 74 (72-75) | 71 (69-74) | 60 (59-61) | 59 (58-61) | 61 (59-63) |
| Cervix | - | - | 73 (71-74) | - | - | 70 (69-72) |
| Kidney and renal pelvis | 67 (66-68) | 66 (64-67) | 69 (68-71) | 60 (59-61) | 58 (56-59) | 64 (62-65) |
| Non-Hodgkin lymphoma | 66 (65-67) | 63 (62-65) | 69 (68-70) | 59 (58-59) | 55 (54-56) | 63 (61-64) |
| Colorectal | 64 (63-65) | 63 (62-64) | 65 (64-66) | 54 (54-55) | 52 (52-53) | 56 (56-57) |
| Larynx | 63 (61-66) | 64 (61-66) | 63 (57-68) | 55 (53-57) | 54 (52-57) | 57 (52-62) |
| Oral | 63 (62-64) | 60 (59-62) | 68 (65-70) | 56 (55-57) | 53 (52-55) | 62 (60-63) |
| Leukemia | 58 (57-59) | 58 (56-59) | 59 (57-60) | 51 (50-52) | 50 (48-51) | $52(51-54)$ |
| Ovary | - | - | $44(42-45)$ | - | - | 41 (40-42) |
| Multiple myeloma | 42 (40-43) | 42 (40-45) | 41 (38-43) | 36 (35-38) | 36 (34-38) | 36 (34-39) |
| Stomach | 25 (23-26) | 23 (21-24) | 28 (26-30) | 21 (20-22) | 19 (18-20) | 25 (23-27) |
| Brain/CNS | 24 (23-26) | 22 (21-24) | 28 (26-29) | $24(23-25)$ | 21 (20-23) | 27 (25-29) |
| Liver | 19 (17-21) | 19 (17-21) | 20 (17-24) | 17 (16-19) | 17 (15-19) | 19 (16-22) |
| Lung and bronchus | 17 (17-17) | 14 (14-15) | 20 (19-20) | 15 (15-15) | 12 (12-13) | 18 (17-18) |
| Esophagus | 14 (12-15) | 13 (12-15) | 17 (14-20) | 12 (11-13) | 11 (10-13) | 16 (13-19) |
| Pancreas | 8 (7-8) | 7 ( 6-8) | 8 ( 7-9) | 7 (6-7) | 6 ( 5-7) | 7 ( 6-8) |

* 2017 page 85: Table 4.1: Tumour-based prevalence for selected cancers by prevalence duration and sex, Canada, January 1, 2009

TABLE 4.1 Tumour-based prevalence for selected cancers by prevalence duration and sex, Canada,* January 1, 2009

|  | 10-year (diagnosed since 1999) |  |  | 5-year (diagnosed since 2004) |  |  | 2-year (diagnosed since 2007) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Total | Males | Females | Total | Males | Females | Total | Males | Females |
| All cancers | 840,985 | 423,760 | 417,225 | 520,025 | 266,175 | 253,855 | 247,310 | 127,775 | 119,535 |
| Prostate | 176,365 | 176,365 | - | 105,180 | 105,180 | - | 46,295 | 46,295 | - |
| Breast | 158,430 | 1,045 | 157,380 | 90,685 | 640 | 90,050 | 39,695 | 285 | 39,410 |
| Colorectal | 105,195 | 56,650 | 48,545 | 67,215 | 36,860 | 30,360 | 32,610 | 18,130 | 14,480 |
| Melanoma | 39,495 | 19,895 | 19,600 | 23,365 | 11,985 | 11,380 | 10,640 | 5,530 | 5,105 |
| Lung and bronchus ${ }^{\dagger}$ | 39,350 | 18,435 | 20,920 | 29,920 | 14,165 | 15,755 | 18,755 | 9,100 | 9,650 |
| Non-Hodgkin lymphoma | 36,220 | 19,140 | 17,080 | 23,145 | 12,440 | 10,705 | 10,760 | 5,900 | 4,865 |
| Bladdert | 34,255 | 25,650 | 8,610 | 21,130 | 15,945 | 5,180 | 9,940 | 7,530 | 2,410 |
| Uterus (body, NOS) | 31,610 | - | 31,610 | 18,540 | - | 18,540 | 8,450 | - | 8,450 |
| Thyroid | 30,930 | 6,515 | 24,410 | 19,240 | 4,125 | 15,120 | 8,625 | 1,935 | 6,695 |
| Kidney and renal pelvis | 24,175 | 14,435 | 9,740 | 15,195 | 9,205 | 5,995 | 7,480 | 4,500 | 2,980 |
| Leukemia | 22,510 | 13,040 | 9,470 | 14,620 | 8,505 | 6,120 | 7,150 | 4,180 | 2,970 |
| Oral | 19,510 | 12,835 | 6,675 | 12,145 | 8,070 | 4,080 | 5,960 | 4,005 | 1,950 |
| Ovary | 10,695 | - | 10,695 | 7,025 | - | 7,025 | 3,535 | - | 3,535 |
| Cervix | 10,200 | - | 10,200 | 5,500 | - | 5,500 | 2,480 | - | 2,480 |
| Testis | 7,935 | 7,935 | - | 4,210 | 4,210 | - | 1,755 | 1,755 | - |
| Multiple myeloma | 7,460 | 4,100 | 3,360 | 5,615 | 3,110 | 2,510 | 2,885 | 1,560 | 1,320 |
| Stomach | 7,420 | 4,625 | 2,790 | 5,170 | 3,250 | 1,920 | 3,045 | 1,955 | 1,095 |
| Brain/CNS | 7,385 | 4,015 | 3,370 | 4,790 | 2,680 | 2,110 | 2,735 | 1,580 | 1,155 |
| Hodgkin lymphoma | 7,160 | 3,890 | 3,270 | 3,905 | 2,100 | 1,805 | 1,685 | 900 | 785 |
| Larynx ${ }^{+}$ | 5,575 | 4,625 | 955 | 3,415 | 2,830 | 585 | 1,645 | 1,375 | 275 |
| Pancreas | 3,750 | 1,845 | 1,905 | 3,140 | 1,560 | 1,575 | 2,320 | 1,165 | 1,155 |
| Liver | 2,985 | 2,245 | 745 | 2,295 | 1,725 | 575 | 1,455 | 1,080 | 370 |
| Esophagus | 2,740 | 2,035 | 710 | 2,165 | 1,610 | 555 | 1,485 | 1,130 | 355 |

## Works Cited

Government of Canada and the Canadian Cancer Society et al. Canadian Cancer Statistics 2017: Special Topic: Pancreatic Cancers. Government of Canada and the Canadian Cancer Society. 2017. Web. Access: <http://www.cancer.ca/~/media/ cancer.ca/CW/cancer\ information/cancer\ 101/ Canadian\%20cancer\%20statistics/Canadian-Cancer-Statistics-2017-EN.pdf?la=en>

Government of Canada and the Canadian Cancer Society et al. Canadian Cancer Statistics 2016: Special Topic: HPV-Associated Cancers. Government of Canada and the Canadian Cancer Society. 2016. Web. Access: <http://www.cancer.ca/~/media/ cancer.ca/CW/cancer\ information/cancer\ 101/Canadian\ cancer\ statistics/ Canadian-Cancer-Statistics-2016-EN.pdf?la=en>

